457Blair DR, Lyttle CS, Mortensen JM, et al. A nondegenerate code of deleterious variants in
Mendelian loci contributes to complex disease risk. Cell. 2013;155:70–80.
Bras JM, Singleton AB. Exome sequencing in Parkinson’s disease. Clin Genet. 2011;80:104–9.
Buzzi MG. Pathways to the best fi t of triptans for migraine patients. Cephalalgia. 2008;28 Suppl
2:21–7.
Byun E, Caillier SJ, Montalban X, et al. Genome-wide pharmacogenomic analysis of the response
to interferon beta therapy in multiple sclerosis. Arch Neurol. 2008;65:337–44.
Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepi-
leptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive
patients with drug-refractory epilepsy. Epilepsia. 2010;51:797–804.
Chang CC, Lui CC, Lee CC, et al. Clinical signifi cance of serological biomarkers and neuropsy-
chological performances in patients with temporal lobe epilepsy. BMC Neurol. 2012;12:15.
Chasman DI, Schürks M, Anttila V, et al. Genome-wide association study reveals three susceptibil-
ity loci for common migraine in the general population. Nat Genet. 2011;43:695–8.
Chen P, Yan Q, Xu H, et al. The effects of ABCC2 G1249A polymorphism on the risk of resistance to
antiepileptic drugs: a meta-analysis of the literature. Genet Test Mol Biomarkers. 2014;18:106–11.
Choy M, Dubé CM, Patterson K, et al. A novel, noninvasive, predictive epilepsy biomarker with
clinical potential. J Neurosci. 2014;34:8672–84.
Comabella M, Vandenbroeck K. Pharmacogenomics and multiple sclerosis: moving toward indi-
vidualized medicine. Curr Neurol Neurosci Rep. 2011;11:484–91.
Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter gene-polymorphisms are potential pharma-
cogenetic markers for mitoxantrone response in multiple sclerosis. Brain. 2009;132:2517–30.
Cramer SC. Use of imaging in restorative stroke trials. Stroke. 2009;40(3 Suppl):S28–9.
Davidson J, Cusimano MD, Bendena WG, et al. Post-traumatic brain injury: genetic susceptibility
to outcome. Neuroscientist 2014. pii: 1073858414543150.
Do CB, Tung JY, Dorfman E, et al. Web-based genome-wide association study identifi es two novel
loci and a substantial genetic component for Parkinson’s disease. PLoS Genet. 2011;7:e1002141.
Dreses-Werringloer U, Lambert JC, Vingtdeux V, et al. A polymorphism in CALHM1 infl uences
Ca2+ homeostasis, Abeta levels, and Alzheimer’s disease risk. Cell. 2008;133:1149–61.
Dresler M, Spoormaker VI, Beitinger P, et al. Neuroscience-driven discovery and development of
sleep therapeutics. Pharmacol Ther. 2014;141:300–34.
Epi4K Consortium, Epilepsy Phenome/Genome Project, Allen AS, Berkovic SF, Cossette P, et al.
De novo mutations in epileptic encephalopathies. Nature 2013;501:217–21.
Escalante-Santiago D, Feria-Romero IA, Ribas-Aparicio RM, et al. MDR-1 and MRP2 gene poly-
morphisms in Mexican epileptic pediatric patients with complex partial seizures. Front Neurol.
2014;5:184.
Falkenberg VR, Gurbaxani BM, Unger ER, Rajeevan MS. Functional genomics of serotonin
receptor 2A (HTR2A): interaction of polymorphism, methylation, expression and disease asso-
ciation. Neuromolecular Med. 2011;13:66–76.
Feng JF, Zhang KM, Jiang JY, et al. Effect of therapeutic mild hypothermia on the genomics of the
hippocampus after moderate traumatic brain injury in rats. Neurosurgery. 2010;67:730–42.
Gabelle A, Roche S, Lehmann S. CSF biomarkers: proteomics investigations and clinical applica-
tions in neurodegenerative disorders. Rev Neurol (Paris). 2009;165:213–22.
Gaitatzis A, Sander J, Gaitatzis A, et al. The long-term safety of antiepileptic drugs. CNS Drugs.
2013;27:435–55.
Gentile G, Borro M, Simmaco M, Missori S, Lala N, Martelletti P. Gene polymorphisms involved
in triptans pharmacokinetics and pharmacodynamics in migraine therapy. Expert Opin Drug
Metab Toxicol. 2011;7:39–47.
Gotovac K, Hajnšek S, Pašić MB, et al. Personalized medicine in neurodegenerative diseases: how
far away? Mol Diagn Ther. 2014;18:17–24.
Grossman I, Avidan N, Singer C, et al. Pharmacogenetics of glatiramer acetate therapy for multiple
sclerosis reveals drug-response markers. Pharmacogenet Genomics. 2007;17:657–66.
Grover S, Kukreti R. A systematic review and meta-analysis of the role of ABCC2 variants on drug
response in patients with epilepsy. Epilepsia. 2013;54:936–45.
References